Molecular technology and pancreatic cancer

British Journal of Surgery

Volumn 87, Issue 7, 2000, Pages 840-853

  Manu, M ^a,b   Buckels, J ^a,b   Bramhall, S ^a,b  

^a Department of Surgery ^*  (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANTIBODY; COMPLEMENTARY RNA; FLOXURIDINE; FLUCYTOSINE; GANCICLOVIR; GASTRIMMUNE; GASTRIN; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PRODRUG; PROTEIN FARNESYLTRANSFERASE; PROTEIN INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG;

CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHRONIC PANCREATITIS; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG METABOLISM; DRUG POTENCY; DRUG TOXICITY; FAMILIAL CANCER; GENE AMPLIFICATION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HIGH RISK POPULATION; HUMAN; MEDICAL TECHNOLOGY; MOLECULAR BIOLOGY; ONCOGENE; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SUICIDE GENE; SURGICAL MORTALITY; TARGET CELL; TELOMERE; TUMOR SUPPRESSOR GENE;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR BIOLOGY; PANCREATIC NEOPLASMS; PEDIGREE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 0033931891     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.2000.01510.x     Document Type: Review

References (186)

1. Klein G, Klein E. Evolution of tumours and the impact of molecular oncology. Nature 1985; 315: 190-5.
2. Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA et al. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992; 102: 230-6.
3. Pellegata NS, Losekoot M, Fodde R, Pugliese V, Saccomanno S, Renault B et al. Detection of K-ras mutations by denaturing gradient gel electrophoresis (DGGE): a study on pancreatic cancer. Anticancer Res 1992; 12: 1731-5.
4. Yanagisawa A, Ohtake K, Ohashi K, Hori M, Kitagawa T, Sugano H et al. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 1993; 53: 953-6.
5. Grunewald K, Lyons J, Frohlich A, Feichtinger H, Weger RA, Schwab G et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989; 43: 1037-41.
6. Gonzalez-Cadavid NF, Zhou D, Battifora H, Bar-Eli M, Cline MJ. Direct sequencing analysis of exon 1 of the c-K-ras gene shows a low frequency of mutations in human pancreatic adenocarcinomas. Oncogene 1989; 4: 1137-40.
7. Mariyama M, Kishi K, Nakamura K, Obata H, Nishimura S. Frequency and types of point mutation at the 12th codon of the c-Ki-ras gene found in pancreatic cancers from Japanese patients. Jpn J Cancer Res 1989; 80: 622-6.
8. Shibata D, Capella G, Perucho M. Mutational activation of the c-Ki-ras gene in human pancreatic carcinoma. Baillieres Clin Gastroenterol 1990; 4: 151-69.
9. Hruban RH, van-Mansfeld AD, Offerhaus GJ, van-Weering DH, Allison DC, Goodman SN et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143: 545-54.
10. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-54.
11. Smit VT, Boot AJ, Smits AM, Fleuran GJ, Cornelisse CJ, Bos JL. K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nuc Acids Res 1988; 16: 7773-82.
12. Tada M, Yokosuka O, Omata M, Ohio M, Isono K. Analysis of ras gene mutations in biliary and pancreatic tumors by polymerase chain reaction and direct sequencing. Cancer 1990; 66: 930-5.
13. Montijima K, Tsunoda T, Kanematsu T, Nagata Y, Urano T, Shiku H. Distinguishing pancreatic carcinoma from other periampullary carcinomas by analysis of mutations in the Kirsten-ras oncogene. Ann Surg 1991; 214: 657-62.
14. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54: 1556-60.
15. Dergham ST, Dugan MC, Kucway R, Du W, Kamarauskiene DS, Vaitkevicius VK et al. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int J Pancreatol 1997; 21: 127-43.
16. Banerjee SK, Makdisi WF, Weston AP, Campbell DR. A two-step enriched-nested PCR technique enhances sensitivity for detection of codon 12 K-ras mutations in pancreatic adenocarcinoma. Pancreas 1997; 15: 16-24.
17. Barton C, Neoptolemos JP, Lemoine N. Mutational activation of Ki-ras and p53 both occur at an early stage in human pancreatic tumourigenesis. Updating Course on Pancreatic Diseases. Genoa, April 1992 (Abstract).
18. Kalthoff H, Schmidt A, Roeder C, Kasche D, Lauer G, Maacke H et al. Genomic alterations of p53 in pancreatic cancer. European Pancreatic Club. Germany, October 1992 (Abstract).
19. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 27-32.
20. Hahn SA, Schutte M, Shamsul Hoque ATM, Moskaluk CA, da Costa LT, Rozenblum E et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-3.
21. Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells SA Jr, Goodfellow PJ. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes Chromosomes Cancer 1995; 14: 189-95.
22. Hahn SA, Hoque AT, Moskaluk CA, da Costa LT, Schutte M, Rozenblum E et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 1996; 56: 490-4.
23. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C,
24. Kloppel G et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64: 1076-82.
25. Ruggeri B, Zhang S-Y, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJP. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992; 7: 1503-11.
26. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993; 142: 1534-43.
27. Casey G, Yainanaka Y, Friess H, Kobrin MS, Lopez ME, Buchler M et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993; 69: 151-60.
28. Zhang SY, Ruggeri B, Agarwal P, Sorling AF, Obara T, Ura H et al. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 1994; 118: 150-4.
29. Kasuya K, Watanabe H, Nakasako T, Ajioka Y, Koyanagi Y. p53 protein overexpression and K-ras codon 12 mutation in pancreatic ductal carcinoma: correlation with histologic factors. Pathol Int 1997; 47: 531-9.
30. Lemoine NR. Genetic intervention for therapy and prevention of pancreatic cancer. Dig Surg 1995; 11: 170-7.
31. Lynch HT, Smyrk T, Kern SE, Hruban RH, Lightdale CJ, Lemon SJ et al. Familial pancreatic cancer: a review. Semin Oncol 1996; 23: 251-75.
32. Ehrenthal D, Haeger L, Griffin T, Compton C. Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer 1987; 59: 1661-4.
33. Comfort MW, Steinberg AG. Pedigree of a family with hereditary chronic relapsing pancreatitis. Gastroenterology 1952; 21: 54-63.
34. Jagelman DG, DeCosseJJ, Bussey HJR, The Leeds Castle Polyposis Group. Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet 1988; i: 1149-51.
35. Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJA, Gittelsohn AM, Booker SV et al. Increased risk of cancer in the Peutz-Jeghers syndrome. New Engl J Med 1987; 316: 1511-14.
36. Lynch HT, Voorhees GJ, Lanspa SJ, McGreevy PS, Lynch JF. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer 1985; 52: 271-3.
37. Danes BS, Lynch HT. A familial aggregation of pancreatic cancer. An in vitro study. JAMA 1982; 247: 2798-802.
38. Taylor AMR. Ataxia telangiectasia genes and predisposition to leukaemia, lymphoma and breast cancer. Br J Cancer 1992; 66: 5-9 (Editorial).
39. Davidson P, Costanza D, Swieconek JA, Harris JB. Hereditary pancreatitis. A kindred without gross aminoaciduria. Ann Intern Med 1968; 68: 88-96.
40. Jagelman DG. Extracolonic manifestations of familial polyposis coli. Cancer Genet Cytogenet 1987; 27: 319-25.
41. Lynch HT, Frichot BC, Lynch P, Lynch J, Gurigis HA. Family studies of malignant melanoma and associated cancer. Surg Gynecol Obstet 1975; 141: 517-22.
42. Lynch HT, Fusaro RM. Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 1991; 6: 127-31.
43. DerKinderen DJ, Koten JW, Den Otter W, Tan KEWP, Beemer FA. Retinoblastoma, melanoma, and pancreatic cancer. Lancet 1986; ii: 1335-6 (Letter).
44. DerKinderen DJ, Koten JW, Nagelkerke NJD, Tan KEWP, Beemer FA, Den Otter W. Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. Int J Cancer 1988; 41: 499-504.
45. DerKinderen DJ, Koten JW, Wolterbeek R, Beemer FA, Tan KEWP, Den Otter W. Non-ocular cancer in hereditary retinoblastoma survivors and relatives. Opthalmic Paediatr Genet 1987; 8: 23-5.
46. Tomita T, Vachal E, Rengachary S, Watanabe I. Occult adenocarcinoma of the pancreas in a patient with Lindau's disease. Dig Dis 1978; 23: 80-3s.
47. Sholman L, Swift M. Pancreatic carcinoma and diabetes mellitus in families of ataxia-telangiectasia probands. Am J Hum Genet 1972; 24: 48.
48. Gordis L, Gold EB. Epidemiology of pancreatic cancer. J World J Surg 1984; 8: 808-21.
49. Keller RT, Logan GM Jr. Adenocarcinoma of the pancreas associated with neurofibromatosis. Cancer 1977; 39: 1264-6.
50. Ghadirian P, Boyle P, Simard A, Baillargeon J, Maisonneuve P, Perret C. Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int J Pancreatol 1991; 10: 183-96.
51. Lynch HT, Fitzsimmons ML, Smyrk TC, Lanspa SJ, Watson P, McClellan J et al. Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. Am J Gastroenterol 1990; 85: 54-60.
52. Dat NM, Sontag SJ. Pancreatic carcinoma in brothers. Ann Intern Med 1982; 97: 282.
53. Friedman JM, Fialkow PJ. Carcinoma of the pancreas in four brothers. Birth Defects Orig Artic Ser 1976; 12: 145-50.
54. MacDermott RP, Kramer P. Adenocarcinoma of the pancreas in four siblings. Gastroenterology 1973; 65: 137-9.
55. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333: 970-4.
56. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. New Engl J Med 1995; 333: 975-7.
57. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK Jr, Perrault J et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Int 1997; 89: 442-6.
58. Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996; 14: 141-5.
59. Whitcomb DC, Preston RA, Aston CE, Sossenheimer MJ, Barua PS, Zhang Y et al. A gene for hereditary pancreatitis maps to chromosome 7q35. Gastroenterology 1996; 110: 1975-80.
60. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996; 13: 117-19.
61. Schutte M, da Costa LT, Hahn SA, Moskaluk C, Shamsul Hoque ATMS, Rozenblum E et al. Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci USA 1995; 92: 5950-4.
62. Porter A. Gene targeting as an approach to gene therapy. In: Lemoine NR, Cooper DN, eds. Gene Therapy. Oxford: Bios, 1996: 169-90.
63. Bottger T, Zech J, Weber W, Sorger K, Junginger T. Prognostically relevant factors in ductal pancreatic cancer. Chirurg 1989; 60: 521-8.
64. Bottger TC, Storkel S, Wellek S, Stockle M, Junginger T. Factors influencing survival after resection of pancreatic cancer. A DNA analysis and a histomorphologic study. Cancer 1994; 73: 63-73.
65. Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991; 161: 120-4.
66. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13 560 patients with pancreatic cancer, and incidence of the disease in the West Midlands: an epidemiological study. Br J Surg 1995; 82: 111-15.
67. Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 1987; 60: 2284-303.
68. Livingston EH, Welton ML, Reber HA. Surgical treatment of pancreatic cancer. The United States experience. Int J Pancreatol 1991; 9: 153-7.
69. Nagakawa T, Konishi I, Ueno K, Ohta T, Akiyama T, Kayahara M et al. Surgical treatment of pancreatic cancer. The Japanese experience. Int J Pancreatol 1991; 9: 135-43.
70. Oi I. Early detection of small pancreatic carcinoma. GANN Monograph on Cancer Research 1986; 31: 147-9.
71. Haglund C, Kuusela P, Roberts PJ. Tumour markers in pancreatic cancer. Ann Chir Gynaecol 1989; 78: 41-53.
72. Bovo P, Rigo L, Togni M, Montesi G, Di-Francesco V, Brunori MP et al. Rapid diagnosis of pancreatic cancer by combination of ultrasonography and serum tumour markers CA 19-9 and CA 50. Ital J Gastroenterol 1993; 25: 477-81.
73. Endo Y, Morii T, Tamura H, Okuda S. Cytodiagnosis of pancreatic malignant tumors by aspiration under direct vision, using a duodenal fiberscope. Gastroenterology 1974; 67: 944-51.
74. Farini R, Nitti D, Del Favero G, Rossi CR, Constantin G, Rebuffi A et al. CEA concentration and cytology in duodenal fluid collected during the Secretin-Pancreozymin test. Attempt at an early diagnosis of pancreatic carcinoma by means of simple procedure. Hepatogastroenterology 1980; 27: 213-16.
75. Tatsuta M, Yamamura H, Yamamoto R, Okano Y, Morii T, Okuda S. Values of CAI9-9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumour. Cancer 1985; 56: 2669-73.
76. Ryan ME. Cytologic brushings of ductal lesions during ERCP. Gastrointest Endosc 1991; 37: 139-42.
77. Burmer GC, Ravinovitch PS, Loeb LA. Analysis of c-Ki-ras mutations in human colon carcinoma by cell sorting, polymerase chain reaction, and DNA sequencing. Cancer Res 1989; 49: 2141-6.
78. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of the polymerase chain reaction products. Oncogene 1990; 5: 1037-43.
79. Tada M, Omata M, Ohto M. Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology 1991; 100: 233-8.
80. Tada M, Omata M, Kawai S, Saisho H, Ohto M, Saiki RK et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993; 53: 2472-1.
81. Neville EM, Ellison G, Kiaris H, Stewart M, Spandidos DA, Fox JC et al. Detection of K-ras mutations in non-small cell lung carcinoma. Int J Oncol 1995; 7: 511-14.
82. Greider CW, Blackburn EH. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 1987; 51: 887-98.
83. Aleyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997; 90: 785-95.
84. Hiyama E, Kodama T, Shinbara K, Iwao T, Itoh M, Hiyama K et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 1997; 57: 326-31.
85. Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunohistochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990; 5: 893-9.
86. Hall PA, Domizio P, Slavin G, Levison DA. Immunohistochemistry in district general hospitals in England and Wales. J Clin Pathol 1987; 40: 1305-9.
87. Gullo L, Pezzilli R, Morselli-Labate AM. Diabetes and the risk of pancreatic cancer. Italian Pancreatic Cancer Study Group. N Engl J Med 1994; 331: 81-4.
88. Karmody AJ, Kyle J. The association between carcinoma of the pancreas and diabetes mellitus. Br J Surg 1969; 56: 362-4.
89. Trumper LH, Burger B, von-Bonin F, Hintze A, von-Blohn G, Pfreundschuh M et al. Diagnosis of pancreatic adenocarcinoma by polymerase chain reaction from pancreatic secretions. Br J Cancer 1994; 70: 278-84.
90. Watanabe H, Sawabu N, Ohta H, Satomura Y, Yamakawa O, Motoo Y et al. Identification of K-ras oncogene mutations in the pure pancreatic juice of patients with ductal pancreatic cancers. Jpn J Cancer Res 1993; 84: 961-5.
91. Kondo H, Sugano K, Fukayama N, Kyogoku A, Nose H, Shimada K et al. Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer 1994; 73: 1589-94.
92. Iwao T, Hiyama E, Yokoyama T, Tsuchida A, Hiyama K, Murakami Y et al. Telomerase activity for the preoperative diagnosis of pancreatic cancer. J Natl Cancer Inst 1997; 89: 1621-3.
93. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994; 54: 3568-73.
94. Niederau C, Grendell JH. Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers. Pancreas 1992; 7: 66-86.
95. Ihalainen J, Taavitsainen M, Salmivaara T, Palotie A. Diagnosis of pancreatic lesions using fine needle aspiration cytology: detection of K-ras point mutations using solid phase minisequencing. J Clin Pathol 1994; 47: 1082-4.
96. Villaneuva A, Balart J, Reyes G. Detection of c-K-ras point mutations in fine needle aspirates of pancreatic masses. Int J Pancreatol 1993; 14: 91-2.
97. Earnhardt RC, McQuone SJ, Minasi JS, Feldman PS, Jones RS, Hanks JB. Intraoperative fine needle aspiration of pancreatic and extrahepatic biliary masses. Surg Gynecol Obstet 1993; 177: 147-52.
98. Shibata D, Almoguera C, Forrester K, Dunitz J, Martin SE, Cosgrove MM et al. Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Res 1990; 50: 1279-83.
99. Urban T, Ricci S, Grange JD, Lacave R, Boudghene F, Breittmayer F et al. Detection of c-Ki-ras mutation by PCR/ RFLP analysis and diagnosis of pancreatic adenocarcinomas. J Natl Cancer Inst 1993; 85: 2008-12.
100. Apple SK, Hecht JR, Novak JM, Nieberg RK, Rosenthal DL, Grody WW. Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smears. Am J Clin Pathol 1996; 105: 321-6.
101. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982; 30: 403-8.
102. Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 1994; 69: 809-16.
103. Laurent-Puig P, Lubin R, Semhoun-Ducloux S, Pelletier G, Fourre C, Ducreux M et al. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. Gut 1995; 36: 455-8.
104. Friess H, Yamanaka Y, Buchler M, Eben M, Beger HG, Gold LI et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993; 105: 1846-56.
105. Friess H, Yamanaka Y, Kobrin MS, Do DA, Buchler MW, Korc M. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res 1995; 1: 1413-20.
106. Rattner DW. Pancreatic cancer in 1992: has any progress been noted? Mayo Clin Proc 1992; 67: 907-9.
107. Williamson RCN. Pancreatic cancer: the greatest oncological challenge. BMJ 1988; 296: 445-6.
108. Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, Clayman GL. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994; 54: 3662-7.
109. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
110. Chen PL, Chen YM, Bookstein R, Lee WH. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990; 250: 1576-80.
111. Lemoine NR. Molecular advances in pancreatic cancer. Digestion 1997; 58: 550-6.
112. Redston MS, Caldas C, Seymour AB, Hruban RH, da-Costa L, Yeo CJ et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54: 3025-33.
113. Kalthoff H, Schmidt A, Roeder C, Schmeigel W. Alterations of p53 in benign lesions outnumber those in their malignant counterpart. Int J Pancreatol 1993; 14: 92.
114. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G et al. P53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 1993; 8: 289-93.
115. Ruggeri BA, Huang L, Berger D, Chang H, Klein-Szanto AJ, Goodrow T et al. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer 1997; 79: 700-16.
116. Frebourg T, Sadelain M, Ng YS, Kassel J, Friend SH. Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer Res 1994; 54: 878-81.
117. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994; 86: 1458-62.
118. Clayman GL, Trapnell BC, Mittereder N, Liu TJ, Eicher S, Zhang S et al. Transduction of normal and malignant oral epithelium by an adenovirus vector: the effect of dose and treatment time on transduction efficiency and tissue penetration. Cancer Gene Ther 1995; 2: 105-11.
119. Clayman GL, el-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995; 55: 1-6.
120. Clayman GL, Liu TJ, Overholt SM, Mobley SR, Wang M, Janot F et al. Gene therapy for head and neck cancer. Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21). Arch Otolaryngol Head Neck Surg 1996; 122: 489-93.
121. Liu TJ, el-Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 1995; 55: 3117-22.
122. Yang C, Cirielli C, Capogrossi MC, Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 1995; 55: 4210-13.
123. Fujiwara T, Grimm EA, Mukhopadhyay T, Cai DW, Owen-Schaub LB, Roth JA. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993; 53: 4129-33.
124. Bookstein R, Demers W, Gregory R, Maneval D, Park J, Wills K. p53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer. Semin Oncol 1996; 23: 66-77.
125. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54: 2287-91.
126. Ashton WT, Karkas JD, Field AK, Tolman RL. Activation by thymidine kinase and potent antiherpetic activity of 2′-nor-2′-deoxyguanosine (2′NDG). Biochem Biophys Res Commun 1982; 108: 1716-21.
127. Aoki K, Yoshida T, Matsumoto N, Ide H, Hosokawa K, Sugimura T et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 1997; 8: 1105-13.
128. Yang L, Hwang R, Pandit L, Gordon EM, Anderson WF, Parekh D. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann Surg 1996; 224: 405-14.
129. Hwang HC, Smythe WR, Elshami AA, Kucharczuk JC, Amin KM, Williams JP et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995; 13: 7-16.
130. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994; 54: 6228-34.
131. Ghoumari AM, Rixe O, Yarovoi SV, Zerrouqi A, Mouawad R, Poynard T et al. Gene transfer in hepatocarcinoma cell lines: in vitro optimization of a virus-free system. Gene Ther 1996; 3: 483-90.
132. Cobb LM, Connors TA, Elson LA, Khan AH, Mitchley BC, Ross WC et al. 2,4-Dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochem Pharmacol 1969; 18: 1519-27.
133. Friedlos F, Court S, Ford M, Denny WA, Springer C. Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Ther 1998; 5: 105-12.
134. Boland MP, Knox RJ, Roberts JJ. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem Pharmacol 1991; 41: 867-75.
135. Roberts JJ, Friedlos F, Knox RJ. CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells. Biochem Biophys Res Commun 1986; 140: 1073-8.
136. Knox RJ, Friedlos F, Jarman M, Davies LC, Goddard P, Anlezark GM et al. Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 1995; 49: 1641-7.
137. Austin EA, Huber BE. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol 1993; 43: 380-7.
138. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 1992; 89: 33-7.
139. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther 1994; 1: 170-5.
140. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 1995; 6: 881-93.
141. Ring CJ, Blouin P, Martin LA, Hurst HC, Lemoine NR. Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumour-selective expression of a prodrug activating enzyme. Gene Ther 1997; 4: 1045-52.
142. Ring CJ, Harris JD, Hurst HC, Lemoine NR. Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Ther 1996; 3: 1094-103.
143. Jaffee EM, Dranoff G, Cohen LK, Hauda KM, Clift S, Marshall FF et al. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 1993; 53(Suppl 10): 2221-6.
144. DiMaio JM, Clary BM, Via DF, Coveney E, Pappas TN, Lyerly HK. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 1994; 116: 205-13.
145. Clary BM, Lyerly HK. Gene therapy and pancreatic cancer. Surg Oncol Clin N Am 1998; 7: 217-49.
146. Lemoine NR, Hall PA. Growth factors and oncogenes in pancreatic cancer. Baillieres Clin Gastroenterol 1990; 4: 815-32.
147. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-9.
148. Jung S, Schluesener HJ. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 1991; 173: 273-6.
149. + T cells recognize a peptide corresponding to a common mutation (13Gly→Asp). Int J Cancer 1994; 56: 40-5.
150. Fossum B, Gedde-Dahl T III, Hansen T, Eriksen JA, Thorsby E, Gaudernack G. Overlapping epitopes encompassing a point mutation (12 Gly→Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells. Eur J Immunol 1993; 23: 2687-91.
151. Gedde-Dahl T III, Fossum B, Eriksen JA, Thorsby E, Gaudernack G. T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction. Eur J Immunol 1993; 23: 754-60.
152. Gedde-Dahl T III, Spurkland A, Eriksen JA, Thorsby E, Gaudernack G. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln→Leu61). Int Immunol 1992; 4: 1331-7.
153. Gedde-Dahl T III, Eriksen JA, Thorsby E, Gaudernack G. T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides. Hum Immunol 1992; 33: 266-74.
154. + T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13→Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol Immunother 1995; 40: 165-72.
155. + T lymphocytes, generated by mutant p21-ras (12 Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 1997; 72: 784-90.
156. Gedde-Dahl T III, Nilsen E, Thorsby E, Gaudernack G. Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras. Cancer Immunol Immunother 1994; 38: 127-34.
157. Mukhopadhyay T, Tainsky M, Cavender AC, Roth JA. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 1991; 51: 1744-8.
158. Aoki K, Yoshida T, Sugimura T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995; 55: 3810-16.
159. Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL et al. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 1996; 14: 1320-6.
160. Barton CM, Lemoine NR. Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br J Cancer 1995; 71:429-37.
161. Watson S, Durrant L, Elston P, Morris D. Inhibitory effects of the gastrin receptor antagonist (L-365 260) on gastrointestinal tumor cells. Cancer 1991; 68: 1255-60.
162. Robertson JF, Watson SA, Hardcastle JD. Effect ofgastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer. Int J Cancer 1995; 63: 69-75.
163. Watson SA, Crosbee DM, Morris DL, Robertson JF, Makovec F, Rovati LC et al. Therapeutic effect of the gastrin receptor antagonist, CR2093 on gastrointestinal tumour cell growth. Br J Cancer 1992; 65: 879-83.
164. Iwase K, Evers BM, Hellmich MR, Guo YS, Higashide S, Kim HJ et al. Regulation of growth of human gastric cancer by gastrin and glycine-extended progastrin. Gastroenterology 1997; 113: 782-90.
165. Darro F, Camby I, Kruczynski A, Pasteels JL, Martinez J, Kiss R. Characterisation of the influence of anti-gastrin, anti-epidermal growth factor, anti-oestradiol, and anti-luteinising hormone releasing hormone antibodies on the proliferation of 27 cell lines from the gastrointestinal tract. Gut 1995; 36: 220-30.
166. Hoosein NM, Kiener PA, Curry RC, Rovati LC, McGilbra DK, Brattain MG. Antiproliferative effects of gastrin receptor antagonists and antibodies to gastrin on human colon carcinoma cell lines. Cancer Res 1988; 48: 7179-83.
167. Watson SA, Michaeli D, Grimes S, Morris TM, Crosbee D, Wilkinson M et al. Anti-gastrin antibodies raised by gastrimmune inhibit growth of the human colorectal tumour AP5. Int J Cancer 1995; 61: 233-40.
168. Watson SA, Michael D, Justin TA, Grimes S, Morris TM, Robinson G et al. Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/ leucovorin in a rat colorectal cancer model. Int J Cancer 1998; 75: 873-7.
169. Watson SA, Michaeli D, Grimes S, Morris TM, Robinson G, Varro A et al. Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res 1996; 56: 880-5.
170. Cottam DW, Rees RC. Regulation of matrix metalloproteinases: their role in tumor invasion and metastasis (review). Int J Oncol 1993; 2: 861-72.
171. Bramhall SR, Neoptolemos JP, Stamp GWH, Lemoine NR. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the
172. Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62: 407-13.
173. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E et al. A matrix metalloproteinase expressed on the surface of invasive rumour cells. Nature 1994; 370: 61-5.
174. Evans J, Bramhall S, Carmichael J, Daniel F, Imrie C, Johnson C et al. A phase II study of marimastat in advanced pancreatic cancer. Ann Oncol 1996; 7:47.
175. Maltese WA. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 1990; 4: 3319-28.
176. Manne V, Roberts D, Tobin A, O'Rourke E, De Virgilio M, Meyers C et al. Identification and preliminarycharacterization of protein-cysteine farnesyltransferase. Proc Natl Acad Sci USA 1990; 87: 7541-5.
177. Schaber MD, O'Hara MB, Garsky VM, Mosser SC, Bergstrom JD, Moores SL et al. Polyisoprenylation of Ras in vitro by a farnesyl-protein transferase. J Biol Chem 1990; 265: 14701-4.
178. Reiss Y, Goldstein JL, Seabra MC, Casey PJ, Brown MS. Inhibition of purified p2 Iras farnesyl : protein transferase by Cys-AAX tetrapeptides. Cell 1990; 62: 81-8.
179. Ito T, Kawata S, Tamura S, Igura T, Nagase T, Miyagawa JI et al. Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl : protein transferase inhibitor. Jpn J Cancer Res 1996; 87: 113-16.
180. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 1995; 55: 5310-14.
181. Kohl NE, Wilson FR, Mosser SD, Giuliani E, deSolms SJ, Conner MW et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 1994; 91: 9141-5.
182. Neoptolemos J, Russell RCG, Bramhall S, Theis B. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of pancreatic specialist units. UK Pancreatic Cancer Group. Br J Sarg 1997; 84: 1370-6.
183. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998; 280: 1747-51.
184. Gordon TA, Burleyson GP, Tielsch JM, Cameron JL. The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg 1995; 221: 43-9.
185. Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Sarg 1995; 222: 638-45.
186. Sosa JA, Bowman HM, Gordon TA, Bass EB, Yeo CJ, Lillemoe KD et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg 1998; 228: 429-38.